PHAXIAM Therapeutics S.A.
PHXMNASDAQHealthcare
$3.10
$-0.17(-5.20%)
Market Cap$19855280
P/E Ratio—
52W High$13.0
52W Low$2.5
PHAXIAM Therapeutics S.A. (PHXM) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PHXM · as of 2026-06-13
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2023-12 | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.02B) | ($0.00B) | ($0.05B) | ($0.07B) | ($0.06B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.01B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Change in Working Capital | ($0.00B) | ($0.01B) | ($0.01B) | $0.01B | $0.01B |
| Net Cash from Operations | ($0.02B) | ($0.03B) | ($0.06B) | ($0.05B) | ($0.04B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.02B) |
| Purchases of Investments | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Sales of Investments | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Investing | $0.00B | $0.04B | ($0.00B) | ($0.00B) | ($0.02B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | ($0.00B) | ($0.00B) | $0.04B | $0.03B | $0.00B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.02B) | ($0.03B) | ($0.06B) | ($0.05B) | ($0.06B) |
| FCF Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-13 · EUR · B
Explore more PHAXIAM Therapeutics S.A. data
About PHAXIAM Therapeutics S.A. (PHXM) Cash Flow Statement
PHAXIAM Therapeutics S.A. generated operating cash flow of ($0.02B) and free cash flow of ($0.02B) for 2023 — a FCF margin of —. Capital expenditure was ($0.00B).
Frequently asked questions
PHXM · 4 questionsPHAXIAM Therapeutics S.A. generated free cash flow of ($0.02B) for 2023, up 22.8% year-over-year.
PHXM free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-13